Form 4: Randal J. Kirk Executes Stock Unit Vesting in Precigen, Inc.

Randal J. Kirk reports the vesting of restricted stock units in Precigen, Inc. on March 9, 2024, resulting in the acquisition of 213,675 shares.

Summary

• On March 9, 2024, Randal J. Kirk vested 213,675 restricted stock units of Precigen, Inc. (PGEN).
• Each restricted stock unit converted into one share of Precigen common stock.
• The restricted stock units were granted on March 9, 2023, and vested fully on the one-year anniversary.
• Following the transaction, Mr. Kirk's indirectly held beneficial ownership includes a substantial number of shares through various entities.

Sentiment

Score: 6

Explanation: The document is a standard regulatory filing detailing stock unit vesting, which is neither overtly positive nor negative. It reflects routine compensation practices.

Positives

• The vesting of restricted stock units indicates confidence in the company's future performance.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

This filing is a routine disclosure related to executive compensation and stock ownership, common in the biotechnology industry where stock-based compensation is frequently used.

Comparison to Industry Standards

• Stock-based compensation is a common practice in the biotech industry to align executive incentives with shareholder value.
• Many biotech companies, such as Amgen, Gilead Sciences, and Biogen, utilize restricted stock units as part of their compensation packages.
• The vesting schedules and terms of these units often vary based on company performance and individual contributions.

Stakeholder Impact

• The vesting of stock units may have a minor dilutive effect on existing shareholders.
• The transaction aligns executive interests with those of shareholders.

Key Dates